NYXH wins FDA approval for its leadless, battery-free Genio sleep apnea therapy, backed by strong trial results.

The US FDA has granted approval to Nyxoah’s Genio system for treating individuals with moderate to severe obstructive sleep ...

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Aaeon has turned to Genio processors from fellow Taiwanese company Mediatek for its latest Smark modules. The first Aaeon products to get MediaTek ICs, uCOM-M700 has an octa-core Genio 700, while uCOM ...

After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

“AI can be used as a gym – a place for training, challenge, and growth – or as a diet pill, a way to bypass effort in the ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

Genio is a bilateral hypoglossal nerve stimulation system that consists of an implantable stimulator and a sleep wearable.

The US Food and Drug Administration (FDA) has granted approval to Nyxoah’s Genio system for treating individuals with moderate to severe obstructive sleep apnoea (OSA).

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).